David Weintritt has joined the community-based cancer treatment team at Virginia Cancer Specialists, a U.S. Oncology Network practice.
Cedars-Sinai Cancer has launched a Clinical and Regulatory Sciences Graduate Certificate Program, which begins in the fall of 2022.
The PERLA phase II trial met its primary endpoint of objective response rate by Response Evaluation Criteria in Solid Tumors criteria as determined by blinded independent central review. The trial evaluated Jemperli (dostarlimab) in combination with chemotherapy versus pembrolizumab in combination with chemotherapy in first-line patients with metastatic non-squamous NSCLC.
Researchers at UNC Lineberger Comprehensive Cancer Center have found a possible way to overcome barriers that block effective anti-cancer immune responses, thereby opening the potential for more effective immunotherapies in people.
A collaborative effort between investigators at Roswell Park Comprehensive Cancer Center and the Center for Molecular Immunology in Havana, Cuba, has revealed a new strategy for correcting immune dysfunction in cancer patients.
A new study—published this week in Science Advances—uncovered a previously unknown genetic process that could inform the development of novel treatment options for glioblastoma.
The findings from the 2022 National Youth Tobacco Survey on e-cigarette use among U.S. youth, published by FDA and CDC in Morbidity & Mortality Weekly Report, show that youth use of e-cigarettes remains high, with 2.5 million (9.4%) of the nation’s middle and high school students reporting current e-cigarette use.
Researchers at Baylor College of Medicine found that a key genetic variant risk factor, PNPLA3, plays a synergistic role in increasing the risk for cirrhosis, liver cancer, and liver-related death when combined with alcohol use and obesity.
FDA has granted accelerated approval to Lytgobi (futibatinib) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements.
MD Anderson Cancer Center and ARTIDIS AG have formed a strategic alliance to investigate ARTIDIS technology as a novel treatment-optimization tool for patients with solid tumors in several distinct indications.
